Arcus Biosciences, Inc.’s $75,000,000 “at-the-market” offering of shares


Cooley advised Arcus Biosciences. Gunderson Dettmer advised Cantor Fitzgerald & Co. acting as underwriter on the offering.

Arcus Biosciences, Inc. executed its $75 million “At-the-Market” offering of shares.

Arcus, which trades on the New York Stock Exchange under the ticker symbol “RCUS,” is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities.

Cantor Fitzgerald & Co. acted as underwriter on the offering.

Gunderson Dettmer advised Cantor Fitzgerald & Co. with a team including Jeffrey Vetter (Picture), Richard Blake and Colin Conklin.

Involved fees earner: Richard Blake – Gunderson Dettmer; Colin Conklin – Gunderson Dettmer; Jeffrey Vetter – Gunderson Dettmer;

Law Firms: Gunderson Dettmer;

Clients: Cantor Fitzgerald;

Avatar

Author: Ambrogio Visconti